Relapse after non‐metastatic rhabdomyosarcoma: The impact of routine surveillance imaging on early detection and post‐relapse survival
暂无分享,去创建一个
A. Ferrari | C. Morosi | S. Vennarini | M. Massimino | P. Gasparini | R. Luksch | C. Meazza | F. Spreafico | M. Podda | M. Terenziani | M. Casanova | E. Schiavello | N. Puma | V. Biassoni | S. Chiaravalli | L. Bergamaschi | G. Gattuso | V. Livellara | G. Sironi | O. Nigro | Shushan Hovsepyan
[1] A. Ferrari,et al. Relapse after nonmetastatic rhabdomyosarcoma: Salvage rates and prognostic variables , 2022, Pediatric blood & cancer.
[2] B. Schäfer,et al. Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. , 2022, European journal of cancer.
[3] S. Bielack,et al. Fusion transcripts as liquid biopsy markers in alveolar rhabdomyosarcoma and synovial sarcoma: A report of the Cooperative Weichteilsarkom Studiengruppe (CWS) , 2022, Pediatric blood & cancer.
[4] S. Bortoluzzi,et al. Clinical significance of circulating tumor cells and cell‐free DNA in pediatric rhabdomyosarcoma , 2022, Molecular oncology.
[5] D. Hawkins,et al. Is Detection of Relapse by Surveillance Imaging Associated With Longer Survival in Patients With Rhabdomyosarcoma? , 2022, Journal of pediatric hematology/oncology.
[6] K. McHugh,et al. European guideline for imaging in paediatric and adolescent rhabdomyosarcoma — joint statement by the European Paediatric Soft Tissue Sarcoma Study Group, the Cooperative Weichteilsarkom Studiengruppe and the Oncology Task Force of the European Society of Paediatric Radiology , 2021, Pediatric Radiology.
[7] L. Mascarenhas,et al. Relapsed Rhabdomyosarcoma , 2021, Journal of clinical medicine.
[8] A. Ferrari,et al. Defining the impact of prognostic factors at the time of relapse for nonmetastatic rhabdomyosarcoma , 2020, Pediatric blood & cancer.
[9] J. H. van der Lee,et al. Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience , 2019, Cancer.
[10] A. Ferrari,et al. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. , 2019, The Lancet. Oncology.
[11] James R. Anderson,et al. Risk‐based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group , 2019, Cancer.
[12] J. Merks,et al. Getting control during follow-up visits: the views and experiences of parents on tumor surveillance after their children have completed therapy for rhabdomyosarcoma or Ewing sarcoma , 2019, Supportive Care in Cancer.
[13] R. Lenkinski,et al. Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates. , 2018, Radiology.
[14] James R. Anderson,et al. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M. Stevens,et al. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. , 2018, The Lancet. Oncology.
[16] M. Hauptmann,et al. Radiation Exposure From Pediatric CT Scans and Subsequent Cancer Risk in the Netherlands , 2018, Journal of the National Cancer Institute.
[17] M. Okcu,et al. Does Routine Imaging of Patients for Progression or Relapse Improve Survival in Rhabdomyosarcoma? , 2016, Pediatric blood & cancer.
[18] S. Holland,et al. Cognition and Brain Structure Following Early Childhood Surgery With Anesthesia , 2015, Pediatrics.
[19] K. McHugh,et al. Pediatric oncology surveillance imaging: Two recommendations. Abandon CT scanning, and randomize to imaging or solely clinical follow‐up , 2014, Pediatric blood & cancer.
[20] K. P. Kim,et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study , 2012, The Lancet.
[21] M. Stevens,et al. Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Leonard,et al. Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] Mark L. Greenberg,et al. Imaging in pediatric patients: Time to think again about surveillance , 2010, Pediatric blood & cancer.
[24] K. Domino,et al. Risks of anesthesia or sedation outside the operating room: the role of the anesthesia care provider , 2010, Current opinion in anaesthesiology.
[25] Harlan M Krumholz,et al. Exposure to low-dose ionizing radiation from medical imaging procedures. , 2009, The New England journal of medicine.
[26] A. Schuck,et al. Does the time‐point of relapse influence outcome in pediatric rhabdomyosarcomas? , 2009, Pediatric blood & cancer.
[27] L. Dauer,et al. Let's image gently: Reducing excessive reliance on CT scans , 2008, Pediatric blood & cancer.
[28] E. Robbins,et al. Radiation risks from imaging studies in children with cancer , 2008, Pediatric blood & cancer.
[29] S. Postovsky,et al. Does Regular Follow-up Influence the Survival of Patients With Sarcoma After Recurrence? The Miri Shitrit Pediatric Oncology Department Experience , 2008, Journal of pediatric hematology/oncology.
[30] P. Winkler,et al. Initial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] A. L. Norberg,et al. Stressors in the Daily Life of Parents After a Child's Successful Cancer Treatment , 2007, Journal of psychosocial oncology.
[32] R. Kleinerman. Cancer risks following diagnostic and therapeutic radiation exposure in children , 2006, Pediatric Radiology.
[33] M. Foulkes,et al. Prognosis of children with soft tissue sarcoma who relapse after achieving a complete response. A report from the intergroup rhabdomyosarcoma study I , 2006, Cancer.
[34] A. Donfrancesco,et al. Outcomes and prognostic factors after recurrence in children and adolescents with nonmetastatic rhabdomyosarcoma , 2005, Cancer.
[35] L. Donnelly. Reducing radiation dose associated with pediatric CT by decreasing unnecessary examinations. , 2005, AJR. American journal of roentgenology.
[36] D. Brenner,et al. Estimated risks of radiation-induced fatal cancer from pediatric CT. , 2001, AJR. American journal of roentgenology.
[37] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[38] A. Pappo,et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] D. Hayes. Prognosis of children with soft tissue sarcoma who relapse after achieving a complete response: A report from the intergroup rhabdomyosarcoma study I: R. B. Raney, Jr, W. M. Crist, H. M. Maurer, et al. Cancer 52:44–50, (July), 1983 , 1984 .
[40] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[41] H. Brisse,et al. [Relapse after rhabdomyosarcoma in childhood and adolescence: Impact of an early detection on survival]. , 2017, Bulletin du cancer.
[42] N. Pedersen,et al. Association of Anesthesia and Surgery During Childhood With Long-term Academic Performance , 2017, JAMA pediatrics.
[43] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.